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DOI 10.1016/j.ccr.2010.03.021SUMMARYThe MAP3-kinase TGF-b-activated kinase 1 (TAK1) critically modulates innate and adaptive immune
responses and connects cytokine stimulation with activation of inflammatory signaling pathways. Here,
we report that conditional ablation of TAK1 in liver parenchymal cells (hepatocytes and cholangiocytes)
causes hepatocyte dysplasia and early-onset hepatocarcinogenesis, coinciding with biliary ductopenia
and cholestasis. TAK1-mediated cancer suppression is exerted through activating NF-kB in response to
tumor necrosis factor (TNF) and through preventing Caspase-3-dependent hepatocyte and cholangiocyte
apoptosis. Moreover, TAK1 suppresses a procarcinogenic and pronecrotic pathway, which depends on
NF-kB-independent functions of the IkB-kinase (IKK)-subunit NF-kB essential modulator (NEMO). Therefore,
TAK1 serves as a gatekeeper for a protumorigenic, NF-kB-independent function of NEMO in parenchymal
liver cells.INTRODUCTION
Inflammatory- and stress-related signaling pathways (e.g.,
NF-kB, c-Jun-[N]-terminal-kinase [JNK], p38[MAPK]) closely
interact to modulate basic cellular processes such as hepato-Significance
In most instances, liver cancer arises on the basis of chronic d
modification of inflammatory signaling pathways might repres
carcinoma. The role of the NF-kB pathway in hepatocarcinoge
on the NF-kB-activating IKK complex led to conflicting results
the NF-kB pathway. We demonstrate that depending on the
assigned as a tumor suppressor, activates a protumorigenic
a functional distinction between the IKK subunits and the NF-
ment of liver-cancer-preventive strategies.cyte apoptosis, proliferation, and cancer development (Wagner
and Nebreda, 2009). However, the role of the NF-kB signaling
pathway in the development of hepatocellular carcinoma (HCC)
continues to remain controversial (Vainer et al., 2008). Inhibition
of NF-kB by conditional deletion of the I-kB-kinase subunits Ikk2amage and inflammation, suggesting that pharmacological
ent a potentially effective strategy to prevent hepatocellular
nesis has remained controversial. Genetic studies focusing
when compared with studies focusing on other members of
functionality of TAK1, the IKK subunit NEMO, previously
pathway that is independent of NF-kB. This finding reveals
kB pathway, which might have implications for the develop-
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A Role of TAK1 in Hepatocarcinogenesis(also termed Ikkb) resulted in increased liver tumor formation in
a chemical carcinogenesis model (Maeda et al., 2005). More-
over, conditional deletion of the regulatory IKK-subunit NF-kB
essential modulator (Nemo) (also termed Ikkg) resulted in spon-
taneous hepatocarcinogenesis in 12-month-old mice (Luedde
et al., 2007), suggesting that NEMO functions as a tumor
suppressor in the liver. Notably, a previous study targeting the
superrepressor IkBa has shown that under certain conditions
inhibition of the NF-kB pathway potentially inhibits the malignant
transformation of hepatocytes (Pikarsky et al., 2004). In line, acti-
vation of the canonical and noncanonical NF-kB pathway by
lymphotoxin promotes hepatocarcinogenesis (Haybaeck et al.,
2009). Therefore, the exact role of the IKK complex and NF-kB
in hepatocarcinogenesis remains controversial, and differences
may be due to the mouse model and type of chronic liver
damage inflicted.
The kinase transforming growth factor (TGF)-b-activated
kinase 1 (TAK1) belongs to the family of mitogen-activated
protein kinase kinase kinases (MAP3Ks). It is activated in
response to cytokines like tumor necrosis factor (TNF), as well
as by lipopolysaccharide (LPS) and TGF-b, and is involved in
controlling the activation of p38MAPK, JNK, and NF-kB in
various cellular systems (Rincon and Davis, 2009). Upon TNF
stimulation, TAK1 and its adaptors, TAB2, TAB3, and NEMO,
are recruited to polyubiquinated RIP1, thus allowing TAK1 to
phosphorylate and activate the catalytic IKK subunits (Adhikari
et al., 2007). Although it has been demonstrated that TAK1 is
essential for innate and adaptive immune responses (Sato
et al., 2005; Tang et al., 2008; Wan et al., 2006), its functional
role in liver parenchymal cells remains elusive. We investigated
this in the current study.
RESULTS
Spontaneous Hepatitis, Cholestasis, Hepatocyte
Dysplasia, and Liver Fibrosis in Mice with Conditional
Ablation of TAK1 in Liver Parenchymal Cells
To elucidate the hepatic function of TAK1 in vivo, we generated
mice with conditional deletion of the Tak1-gene (Map3k7) in
liver parenchymal cells (LPC) (TAK1LPC-KO) by intercrossing
TAK1 floxed mice with Alfp-Cre transgenic mice (Kellendonk
et al., 2000; Sato et al., 2005). The hepatic phenotype of
these animals was compared with mice with LPC-specific dele-
tion of Nemo (NEMOLPC-KO). TAK1LPC-KO and NEMOLPC-KO mice
showed efficient ablation of the respective proteins in LPC, as
demonstrated by western blot analysis of whole liver protein
extracts (Figure 1A). By 6 weeks of age, TAK1LPC-KO, but not
NEMOLPC-KO mice already displayed an aberrant liver architec-
ture with numerous small but macroscopically visible nodules
(Figure 1B). This macroscopic appearance coincided with
strongly elevated serum aminotransferase (ALT and AST) and
bilirubin levels (mainly consisting of direct bilirubin [Figure 1C]).
Additionally, elevated levels of circulating alkaline phosphatase
(AP) and glutamate dehydrogenase (GLDH) were detected in
6-week-old TAK1LPC-KO mice (Figure 1C), indicating intrahepatic
cholestasis. Compared with TAK1LPC-KO mice, NEMOLPC-KO
animals displayed a milder increase in ALT/AST at this age,
without significant elevation of bilirubin or cholestatic enzymes
(Figure 1C).482 Cancer Cell 17, 481–496, May 18, 2010 ª2010 Elsevier Inc.We further examined TAK1LPC-KO mice at 20 weeks of age.
These mice displayed an aggravated macroscopic phenotype
with larger nodules and an icteric appearance (Figure 1D), corre-
lating with elevated serum bilirubin levels as compared with
age-matched wild-type (WT), NEMOLPC-KO, as well as 6-week-
old TAK1LPC-KO mice (Figure 1E). ALT and AST levels were still
significantly upregulated in sera of 20-week-old TAK1LPC-KO
mice, but to minor extent than at 6 weeks and to similar extent
as seen in age-matched NEMOLPC-KO mice (Figure 1E). Finally,
all TAK1LPC-KO mice investigated succumbed to death between
14 and 36 weeks of age (n = 9), whereas no spontaneous deaths
were noticed in WT (n = 15) or NEMOLPC-KO mice (n = 15) within
a period of 60 weeks (Figure 1F).
On histological level, numerous areas of focal hepatocyte
necrosis morphologically resembling biliary infarcts could be
detected in TAK1LPC-KO, but not in WT or NEMOLPC-KO livers,
whereas immune cell infiltrates were detected in both mutant
lines, but not in WT mice (Figure 2A and Figures S1A and
S1B> available online). Moreover, nodules displaying cellular
features of dysplasia like anisokaryosis were detected in
TAK1LPC-KO livers (Figure 2B). Hematoxylin and eosin and
pan-cytokeratin (CK) stainings revealed the absence of biliary
epithelial cells and regularly shaped small bile ducts in most
portal tracts of 6- to 8-week-old TAK1LPC-KO compared with
WT and NEMOLPC-KO livers (Figures 2C–2E and Figures S1A–
S1C). Morphometric analyses revealed that biliary ductopenia
in TAK1LPC-KO livers was pronounced within areas of hepatocyte
dysplasia, whereas pre-existing biliary epithelial cells and bile
duct structures were still—but rarely—detected in the border
zone of areas with dysplasia (Figure 2E, lower panel, and
Figure S1D).
Chronic hepatitis and cholestasis lead to liver fibrosis
(Bataller and Brenner, 2005). At 6 weeks of age, TAK1LPC-KO
and NEMOLPC-KO animals displayed signs of periportal liver
fibrosis as detected by Sirius red staining, which progressed
to severe diffused fibrosis in 20- to 29-week-old animals (Fig-
ures 2F and 2G). Livers of 14-week-old TAK1LPC-KO mice and
NEMOLPC-KO mice showed strongly increased hydroxyproline
content (Figure 2H). Moreover, livers of 6-week-old mice dis-
played an upregulation of collagen Ia1 and matrix metallopro-
tease (Mmp)-1 mRNA, further confirming the increased produc-
tion of extracellular matrix (Figure S1E). TGF-b is a crucial
regulator of liver fibrosis (Bataller and Brenner, 2005). All three
TGF-b isoforms were strongly upregulated on mRNA-level in
TAK1LPC-KO mice (Figure S1F). Immunohistochemistry and
western blot analysis revealed that Tgf-b expression was leading
to strong phosphorylation of SMAD2 and SMAD3 in paren-
chymal and nonparenchymal hepatic cells of TAK1LPC-KO mice
(Figures S1G and S1H). Therefore, TAK1 deficiency in paren-
chymal liver cells results in development of hepatic fibrosis.
TAK1 Ablation in LPC Causes Spontaneous Hepatocyte
Apoptosis and Hyperplasia
We further investigated how TAK1 deficiency influences hepato-
cyte cell death and proliferation. Despite frequent necrotic foci in
livers of TAK1LPC-KO mice, we tested if TAK1 also influences
caspase activation and spontaneous apoptosis of hepatocytes.
TUNEL stains revealed dispersed and numerous TUNEL-
positive cells in livers of TAK1LPC-KO and to a lesser extent in
Figure 1. Spontaneous Development of Hepatocyte Damage, Cholestasis, and Spontaneous Death in TAK1LPC-KO Mice
(A) Western blot analysis of whole liver protein extracts from 6-week-old male TAK1LPC-KO, NEMOLPC-KO, and control littermate mice (WT) using antibodies
against TAK1, NEMO, and GAPDH as loading control (kDa, kilodalton).
(B) Representativemacroscopic pictures of 6-week-oldmaleWT (left panel), TAK1LPC-KO (middle panel), and NEMOLPC-KO livers (right panel). Small nodular struc-
tures are observed in livers of TAK1LPC-KO mice (arrows).
(C) Serum level analysis of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total and direct (conjugated) bilirubin, alkaline phosphatase (AP),
and glutamate dehydrogenase (GLDH) in 6-week-old male mice. Results are shown as mean, error bars indicate standard error of the mean (SEM). *p < 0.05;
**p < 0.01; ***p < 0.001 (n = 4 each genotype).
(D) Representative macroscopic pictures of a 20-week-old male WT (left panel), TAK1LPC-KO (middle panel), and NEMOLPC-KO mouse (right panel). Livers of
TAK1LPC-KO mice show multiple nodules (arrows) and a yellow, icteric color.
(E) Analysis of serum ALT, AST, and total bilirubin levels in 20-week-old male WT, TAK1LPC-KO, and NEMOLPC-KO mice. Results are shown as mean, error bars
indicate SEM. **p < 0.01; ***p < 0.001 (n = 4 each genotype).
(F) Kaplan-Meier curve showing spontaneous death of TAK1LPC-KO mice between 16 and 36 weeks of age. ***p < 0.001. WT n = 15, NEMOLPC-KO n = 15, and
TAK1LPC-KO n = 9.
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were identified as hepatocytes (Figures 2I and 2J). Moreover,
cleavage of Caspase-3, a key feature of apoptotic cell death,
occurred in TAK1LPC-KO and to a lesser extent in NEMOLPC-KO
mice but not in WT livers (Figures S1I–S1K), suggesting that
TAK1 deficiency sensitizes hepatocytes to caspase-dependent
apoptosis.
Hepatocyte cell deathwasaccompaniedbyexcessive liver cell
proliferation in TAK1LPC-KO mice, as demonstrated by increased
BrdU incorporation (Figure 2K). Ki67 staining confirmed that thishyperproliferation could mainly be attributed to hepatocytes
(Figure 2L and Figure S1L). In addition, expression of cyclin D1,
cyclin E, and PCNA, key cell-cycle markers for G1-S-phase tran-
sition, were strongly enhanced in livers of TAK1LPC-KO mice
(Figure S1M), underlining the correlation between hepatocyte
cell death and hyperproliferation in these animals.
Early-Onset Hepatocarcinogenesis in TAK1LPC-KO Mice
We further examined whether the dysplasia and hyperprolifera-
tion of hepatocytes detected in livers of TAK1LPC-KO fromCancer Cell 17, 481–496, May 18, 2010 ª2010 Elsevier Inc. 483
Figure 2. Focal Hepatocyte Necrosis, Reduction of Small Portal Bile Ducts, Liver Fibrosis, Increased Cell Death and Proliferation in
TAK1LPC-KO Mice
(A–E) Histological and immunohistochemical analysis on representative liver paraffin sections from 6-week-old male mice. (A) Multiple areas of focal hepatocyte
necrosis (arrows) in livers of TAK1 mutant, but not WT animals. (B) Upper right panel: histological appearance of a nodular area with dysplasia in a TAK1LPC-KO
mouse, adjacent to an area with less dysplasia. Upper left panel: WT control liver. Lower panels: strong enlargement of hepatocyte-nuclei in dysplastic areas of
TAK1LPC-KO livers (right panel) compared with WT livers (left panel). (C and D) Hematoxylin and eosin (H&E) and Cytokeratin (CK) stainings showing the presence
Cancer Cell
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points. Thus, we analyzed 16- to 33-week-old TAK1LPC-KO
mice (5 males and 11 females) for the presence of liver tumors.
Notably, 14 out of 16 mice developed liver tumors, which histo-
logically qualified as HCC (z88% incidence) due to the following
criteria: expansive and tissue infiltrating growth pattern, frequent
hepatocyte mitoses, increased cellularity, nodular structures,
broadening and loss of the regular collagen IV and reticulin
network separating neighboring hepatocytes (Figures 3A and
3B and Table S1). Remarkably, no HCC or liver tumors were
detected in 21- to 26-week-old NEMOLPC-KO mice (n = 6)
(Figure S2 and Table S1), which usually developed HCC at the
age of around 50 weeks (Luedde et al., 2007).
We investigated microdissected TAK1LPC-KO HCC (n = 19)
and age-matched WT livers (n = 8) for chromosomal aberra-
tions. Array comparative genomic hybridization analysis
(aCGH) revealed chromosomal aberrations in all 19 TAK1LPC-
KO HCC samples (Figure 3C), indicating the neoplastic, most
likely malignant nature of the tumors observed. Amplifications
and deletions of chromosomal regions ranged from 0.68 mega-
base (MB) to 151 MB. Of note, the pattern of chromosomal
aberrations showed a common signature in HCC from different
individual TAK1LPC-KO mice (permutation test, p < 0.00001).
A total of 7 out of 19 HCC displayed amplifications on chromo-
some 4, 14 out of 19 HCC analyzed displayed amplifications
on chromosome 8, and 17 out of 19 HCC displayed amplifica-
tions on chromosome 13 (often affecting the whole q-arm)
(Figure 3C). This suggests a functional relationship between
TAK1-dependent signals and chromosomal integrity in hepato-
cytes. Transcriptional analysis revealed significant upregulation
of selected oncogenes and tumor-suppressor genes in micro-
dissected HCC from TAK1LPC-KO mice: among others, FgR
and Jun (chromosome 4), FgfR1 (chromosome 8), Ntrk2 and
Net1 (chromosome 13) were upregulated when compared with
WT livers (conventional t test) (Figure 3D and Table S2).
However, multiple comparison with Bonferroni correction
confirmed significant upregulation only for Ntrk2 (20.58-fold),
Net1 (6.66-fold), and Jun (2.81-fold) (Table S2), which are all
located on affected chromosomes, while many other onco-
genes and tumor-suppressor genes involved in hepatocarcino-of small bile ducts in portal areas of WT (arrows), but not TAK1LPC-KO livers (right p
tract is expected in a TAK1LPC-KO liver (right panel) when compared with strongly p
cells and biliary ducts in an area surrounding a dysplastic nodule, but not within
(F) Representative liver sections of 6- (upper panels) and 28-week-old (lower p
revealing periportal fibrosis in younger mice and severe diffuse liver fibrosis in ol
(G) Densitometric analysis of Sirius red-stained collagen strings from livers of 6-
genotype at 6-week-old mice, n = 4 each genotype at 20- to 29-week-old mice)
*p < 0.05; **p < 0.01.
(H) Hydroxyproline-assay quantifying the collagen content in liver. Results are sh
(I) Spontaneous hepatocyte cell death in 6-week-old TAK1LPC-KO and (to lesser de
liver sections (upper panels: fluorescence on frozen sections, lower panels: perox
nuclei).
(J) Quantification of TUNEL+ hepatocytes in 6-week-old mice. Results are shown
TAK1LPC-KO; n = 7 NEMOLPC-KO, each dot represents the average value per mou
(K) BrdU incorporation analysis to detect S phase positive liver cells of 6-week-old
is marked in blue). Statistical analysis of BrdU+ cells per HPF. Results are shown
(L) Densitometric analysis of Ki67+ hepatocytes in the respective 6- to 9-week-o
*p < 0.05; ***p < 0.001 (n = 6 WT; n = 4 TAK1LPC-KO; n = 6 NEMOLPC-KO; 10 HPF
See also Figure S1.genesis (e.g., p53, c-myc, fos, n-ras) were not significantly dys-
regulated (Table S2).
To further understand if HCCs of TAK1LPC-KO mice could be
classified as malignant tumors, samples were profiled by quan-
titative real-time polymerase chain reaction with a 16-gene
signature that identifies and stratifies liver tumors according to
their degree of differentiation and proliferation rate (Cairo et al.,
2008). As a control, normal liver samples, NEMOLPC-KO samples
as well as samples of aggressive liver tumors from WHV/N-
myc2 p53+/Delta mice (Renard et al., 2000) were added. Unsu-
pervised analysis clearly showed co-clustering of nearly all
the TAK1LPC-KO and NEMOLPC-KO nodules with control tumor
samples, displaying mRNA upregulation of genes involved in
proliferation and cell cycle (Afp, Bub1, Dlg7) and accounting
for a highly transformed molecular phenotype of the samples
(Figure 3E). These data further classify TAK1LPC-KO liver tumors
as HCC.
TAK1 Controls Hepatocyte Apoptosis and Necrosis via
Distinct NF-kB-Dependent and -Independent Pathways
We further analyzed which pathways could mediate the down-
stream effects of TAK1 in LPC. Inducible degradation of IkBa
in response to LPS-injection—a potent inducer of endogenous
TNF secretion (Leist et al., 1995)—was strongly inhibited in the
livers of TAK1LPC-KOmice to a similar extent as observed in NEM-
OLPC-KO mice (Figure 4A). This correlated with the inhibition of
LPS-induced DNA binding of NF-kB in electrophoretic mobility
shift assay analysis (Figure 4B). We furthermore isolated primary
hepatocytes and stimulated them with recombinant TNF. In line
with the massive hepatocyte cell death detected in vivo, primary
hepatocytes isolated from TAK1LPC-KO and from NEMOLPC-KO
mice, although to a lesser extent, showed severe morphological
alterations and underwent cell death immediately upon culturing.
This was not observed in cultures with hepatocytes isolated from
WT mice (data not shown). Interestingly, 1 hr after TNF stimula-
tion, TAK1- and NEMO-deficient hepatocytes demonstrated a
similar defect in the induction of the NF-kB-target genes IkBa
and A20 as compared withWT hepatocytes (Figure 4C). Notably,
JNK was hyperactivated upon LPS-stimulation in TAK1LPC-KO as
compared with WT livers (Figure 4A).anels). (E) Upper panels: no CK+ cells can be detected in areas where a portal
ositive bile ducts in livers of WTmice (left panel). Lower panel: detection of CK+
the nodule of a TAK1LPC-KO liver.
anels) male WT, TAK1LPC-KO, and NEMOLPC-KO mice stained with Sirius red
der TAK1LPC-KO mice (red: collagen deposition).
and 20- to 29-week-old WT, TAK1LPC-KO, and NEMOLPC-KO mice (n = 6 each
. Results are shown as mean, and error bars indicate standard deviation (SD);
own as mean, error bars indicate SEM. *p < 0.05; **p < 0.01 (n = 3).
gree) in NEMOLPC-KO, but not inWTmice, as demonstrated by TUNEL assay on
idase staining on paraffin sections, black arrows indicate TUNEL+ hepatocyte
as mean, and error bars indicate SEM. **p < 0.01; ***p < 0.001. (n = 7 WT; n = 4
se liver, calculated from four high-power-field [HPF] analyses).
mice that underwent repetitive BrdU injections for 2 days (DAPI counterstaining
as mean, and error bars indicate SD. *p < 0.05; **p < 0.01; ***p < 0.001 (n = 3).
ld knockout mice. Results are shown as mean, and error bars indicate SEM.
/mouse liver).
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Figure 3. Early-Onset HCC Development in TAK1LPC-KO Mice
(A) Histological features of different liver tumors in 16- to 33-week-old TAK1LPC-KOmice stained by H/E (left panel, arrow head). Liver tumor with a ‘‘clear-cell-like’’
appearance. The middle and right panels show liver tumors (arrow head) of a size up to 4 mm with eosinophilic cells.
(B) Consecutive slides of a representative liver tumor in a 20-week-old TAK1LPC-KO mouse stained with H/E, Collagen IV, and Silver-Reticulin, showing typical
histological features of human HCC: expansive growth, increased cellularity, loss of collagen IV staining between neighboring hepatocytes and abnormal archi-
tecture, and loss of reticulin fibers.
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A Role of TAK1 in HepatocarcinogenesisBecause it has been previously demonstrated that only
complete, but not partial, inhibition of inducible NF-kB activation
sensitizes hepatocytes to LPS-induced apoptosis (Luedde et al.,
2007), we compared the apoptotic response following LPS stim-
ulation in TAK1LPC-KO and NEMOLPC-KO mice. Correlating with
inhibition of LPS-induced NF-kB activation, TAK1LPC-KO mice
developed massive liver cell apoptosis and liver injury 9 hr after
LPS treatment similar to NEMOLPC-KO mice, as demonstrated
by TUNEL assay, western blot analysis for cleaved Caspase-3,
and measurement of serum ALT levels (Figures 4D–4F). There-
fore, TAK1 has a crucial function, similar to NEMO, in mediating
LPS/TNF-induced activation of NF-kB and protection from
hepatocyte apoptosis. Absence of one of both molecules—
either TAK1 or NEMO—blocks NF-kB induction. However, our
findings demonstrate that not only JNK can be activated in the
absence of TAK1, but that TAK1 inhibits hyperactivation of
JNK in response to LPS injection.
Despite spontaneous hepatocyte apoptosis, TAK1LPC-KO, but
not NEMOLPC-KO, mice showed areas of hepatic necrosis
(Figure 2A and Figure S1A). Therefore, we hypothesized that in
addition to caspase-dependent apoptosis, TAK1 might withhold
additional functions in controlling hepatocyte cell death, and
therefore intercrossed TAK1LPC-KO with floxed Caspase-8
mice (TAK1/Casp8LPC-KO) (Figure S3A). Serological analysis of
6-week-old TAK1/Casp8LPC-KO animals revealed a milder eleva-
tion of ALT levels and similar AST levels in these animals
compared with TAK1LPC-KO single mutants, whereas serum bili-
rubin levels were significantly higher in double mutants than in
the single TAK1LPC-KO mice (Figure S3B). Histologically, areas
of focal necrosis were detected in TAK1/Casp8LPC-KO at earlier
age and even to larger extent than in TAK1LPC-KO animals, prob-
ably reflecting additional proinflammatory effects of a Caspase-8
knockout in hepatocytes as previously suggested (Ben Moshe
et al., 2007). These effects were accompanied by hyperprolifer-
ation, dysplasia and reduction of biliary epithelial cells within
the dysplastic areas (Figure S3C). Western blot analysis con-
firmed a similar expression of PCNA in TAK1/Casp8LPC-KO as
compared with TAK1LPC-KO mice (Figure S3D). However, TAK1/
Casp8LPC-KO mice were devoid of cleaved Caspase-3, as exam-
ined on immunohistochemical and protein level (Figures S3C
and S3D). TAK1/Casp8LPC-KO mice did not spontaneously die
within the observed period of 32 weeks, but showed signs of
growth retardation (Figure S3E). These results strongly suggest
that in addition to controlling NF-kB and caspase-dependent
apoptosis in hepatocytes, TAK1 also suppresses a signaling
pathway that is independent of NF-kB-mediated regulation of
Caspase-3 cleavage and that mediates focal necrosis, dys-
plasia, and biliary ductopenia in the liver.(C) aCGH analysis of HCC from independent TAK1LPC-KO mice. The q-arm of eac
zontal bars within the symbolized chromosomes represent G bands. Chromosom
TAK1LPC-KO mice were hybridized against liver tissue of an age-matched WTmou
sent individual HCC. Individual mice are labeled by horizontal colored bars (TAK
(D) mRNA expression analysis of selected oncogenes located on chromosomes
after multiple comparison (Bonferroni correction) (see Table S2).
(E) A 16-gene profile analysis (heat map) of HCC derived from TAK1LPC-KO (20-
compared to aggressive liver tumors from WHV/N-myc2 p53+/Delta mice. Abo
whereas genes below the dashed white line represent a less proliferative, more
See also Figure S2 and Tables S1 and S2.A NEMO-Dependent but NF-kB-Independent Pathway
Mediates Hepatocyte Necrosis, Dysplasia, and Biliary
Alterations in TAK1LPC-KO Mice
It has been proposed that complexes consisting of TAK1 and
NEMO are not only involved in NF-kB activation, but might also
control alternative cellular pathways (Karin and Gallagher,
2009). We therefore hypothesized that a NEMO-dependent
pathway might be responsible for some of the phenotypes
observed in the TAK1-deficient animals and intercrossed
TAK1LPC-KO with NEMOLPC-KO mice to generate animals with
combined deletion of TAK1 and NEMO in LPC (TAK1/
NEMOLPC-KO).
Surprisingly, TAK1/NEMOLPC-KO mice showed macroscopi-
cally normal livers in contrast to the nodular appearance of
TAK1LPC-KO mice at the age of 6 weeks (Figure 5A). Moreover,
the combined deletion of NEMO and TAK1 completely rescued
mice from the spontaneous death observed in TAK1LPC-KO
mice (Figure 5B). Notably, TAK1/NEMOLPC-KO mice showed
the same degree of liver cell damage on a serological level as
TAK1LPC-KO mice, but had serum bilirubin levels similar to age-
matched WT mice (Figure 5C). In correlation, electron micros-
copy analysis in TAK1/NEMO double mutants revealed
a rescue of the severe ultrastructural signs of cholestasis that
were seen in TAK1 single mutant mice (Figure S4A). Protein
levels of cleaved Caspase-3 in TAK1/NEMOLPC-KO mice were
similar to TAK1LPC-KO livers (Figure 5D). Proliferation and cell
cycle markers cyclin D1 and PCNA were expressed to an
analogous extent in TAK1/NEMOLPC-KO and TAK1LPC-KO mice,
whereas cyclin E1 expression and BrdU incorporation were
decreased in TAK1/NEMOLPC-KO as compared with TAK1LPC-KO
animals (Figures 5D and Figure S4B).
Histological analysis of TAK1/NEMOLPC-KO livers revealed
a complete absence of necrotic and nodular dysplastic areas
(Figure 5E). Moreover, TAK1/NEMOLPC-KO mice maintained
normal portal tract architecture and showed ubiquitous abun-
dance of bile ducts in portal tracts (Figure 5E). Ki67 and cleaved
Caspase-3+ cells were detected to similar extent in TAK1/
NEMOLPC-KO and TAK1LPC-KO mice (Figures S4C–S4E). There-
fore, NEMO functions to mediate focal hepatocyte necrosis,
hepatocyte hyperplasia, hepatocarcinogenesis, cholestasis, and
spontaneous death in TAK1LPC-KO mice.
Mechanisms Driving NEMO-Dependent Dysplasia
and Carcinogenesis in TAK1LPC-KO Livers
To confirm that NEMO promotes hepatocyte dysplasia in
6-week-old TAK1LPC-KO mice, we performed a transcriptional
analysis for expression of alpha-fetoprotein (Afp) and H19, two
established liver tumor markers (Ariel et al., 1998; Okuda,h chromosome is shown and chromosome numbers are indicated. Dark hori-
al deletions are indicated in blue, and amplifications in red. HCC of individual
se and analyzed by aCGH analysis. Columns next to each chromosome repre-
1LPC-KO tumors: n = 19; WT liver samples: n = 8).
4, 8, and 13. Asterisk indicates oncogenes that were significantly upregulated
to 31-week-old mice) and NEMOLPC-KO livers (52-week-old mice). HCC were
ve the dashed line the genes indicating a proliferative phenotype are listed,
differentiated phenotype.
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Figure 4. TAK1 Controls NF-kB- and Caspase-3-Dependent Hepatocyte Apoptosis
(A) Degradation of IkBa and phosphorylation of Jun-N-terminal-kinase (JNK) was examined by western blot analysis on liver extracts from WT, TAK1LPC-KO, and
NEMOLPC-KO mice at the indicated time points after stimulation with bacterial lipopolysaccharides (LPS).
(B) Electrophoretic mobility shift assay (EMSA) on nuclear protein extracts from WT, TAK1LPC-KO and NEMOLPC-KO livers at the indicated time points after LPS
stimulation. In lanes 10 and 11, antibodies against the NF-kB subunits p50 and p65 were added as supershift control. NF-kB activation in response to LPS-injec-
tion is inhibited in TAK1LPC-KO and NEMOLPC-KO compared with WT livers.
(C) Induction of the NF-kB target genesA20 and Ikba in response to TNF stimulation was examined in primary hepatocytes isolated from livers ofWT, TAK1LPC-KO,
and NEMOLPC-KO mice by quantitative RT-PCR. Results are expressed as mean, and error bars denote SD (n = 3 each genotype).
(D) TUNEL assay on liver sections from the indicated mouse lines at 9 hr after LPS injection (original magnification 2003).
(E)Western blot on whole liver protein extracts isolated from the indicatedmouse lines after LPS-injection using an antibody against the cleaved form of Caspase-
3 or GAPDH as loading control.
(F) Liver damage 9 hr after LPS-administration was assessed by measuring serum ALT. Results are expressed as mean, and error bars indicate SD. *p < 0.05;
**p < 0.01; ***p < 0.001 (n = 3 each genotype).
See also Figure S3.
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sion of these tumor markers at 6 weeks of age when malignant
tumors were not yet histologically detectable, whereas this
upregulation was reversed by the additional deletion of NEMO
(Figure 6A). At the age of 21 weeks, no HCC was observed in
livers of TAK1/NEMOLPC-KO mice (Table S1). These data demon-
strate that NEMO, which has been previously assigned as a
tumor suppressor in hepatocytes (Luedde et al., 2007), exhibits
a previously unrecognized prodysplastic function in LPC in the
absence of TAK1.488 Cancer Cell 17, 481–496, May 18, 2010 ª2010 Elsevier Inc.Furthermore, we set out to exclude that the rescue of the
phenotype in TAK1/NEMOLPC-KO animals was due to an NF-
kB-dependent immune response in these animals rather than
an NF-kB-independent, cell-autonomous pathway downstream
of NEMO. Analysis of inflammatory cytokines revealed a strong
but similar elevation of Tnf, interleukin (Il)-6, IL-1b, and inter-
feron-g (IFNg) in 6-week-old TAK1 single- and TAK1/NEMO
double-mutant mice compared with WT mice (Figure S5A).
Moreover, flow cytometry and morphological and immunohisto-
chemical analyses demonstrated no significant difference in the
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A Role of TAK1 in Hepatocarcinogenesisnumber and quality of infiltrating immune cells between livers
of TAK1LPC-KO and TAK1/NEMOLPC-KO mice as investigated
(Figures S5B–S5E).
JNK is an important mediator of hepatocarcinogenesis
(Sakurai et al., 2006), suggesting that hyperactivation of JNK in
TAK1LPC-KO livers in response to LPS might be an important
mediator of the prodysplastic phenotype seen in these animals.
Therefore, we sought to elucidate how hyperactivation of JNK is
mediated in TAK1LPC-KO livers. TAK1/NEMO double-mutant
livers showed reduced JNK-activation in response to LPS-injec-
tion compared with TAK1 single-mutant livers (results of three
independent experiments are presented in Figure 6B). Western
blot analysis revealed that TAK1LPC-KO livers displayed hyperac-
tivation of the MAPK kinases MKK4 and MKK7 in response
to LPS injection (Figure 6C). Thus, this mechanism in TAK1-
deficient LPC is clearly distinct to hepatocytes that are solely
NF-kB defective, which do not show hyperactivation of JNK
by influencing MKK activity in response to TNF but rather display
sustained JNK activation via inactivation of JNK-directed phos-
phatases (Kamata et al., 2005). Because NEMO does not with-
hold a known kinase activity (Hacker and Karin, 2006), we exam-
ined if TAK1 ablation might influence activity of other MAP3
kinases in hepatocytes. As shown in Figure 6C, TAK1LPC-KO
mice showed stronger phosphorylation of the MAP3 kinase
TAO2, a known activator ofMKKs and JNK upon LPS stimulation
(Chen et al., 2003).
To further analyze which NEMO-dependent functions might
mediate dysplasia in TAK1LPC-KO animals, we tested for the
phosphorylation status of known NF-kB-independent targets
of the IKK complex involved in carcinogenesis (reviewed in
Chariot, 2009) in the different knockout lines. No specific
changes in the phosphorylation status of members of the
mTOR pathway (pS6K1 and p4EBP1), of Aurora A and Dok1
were detected between TAK1LPC-KO and TAK1/NEMOLPC-KO
mice (data not shown). However, we found increased phosphor-
ylation of the forkhead transcription factor FOXO3a in livers of
6-week-old TAK1LPC-KO, but not TAK1/NEMOLPC-KOmice, which
was also detected in tumors rather than in nonmalignant
tissue in older TAK1LPC-KO mice, but was not linked with signifi-
cant changes in phosphorylation of the upstream kinase AKT
(Figure 6D). Because IKK-dependent phosphorylation of
FOXO3a mediates carcinogenesis in many tumors (Hu et al.,
2004), this pathway might contribute to NEMO-mediated hepa-
tocarcinogenesis in TAK1LPC-KO mice.
Mechanisms Driving Cholestasis and Ductopenia in
TAK1LPC-KO Livers
We further analyzed the cellular mechanisms responsible for the
development of cholestasis and focal ductopenia in TAK1LPC-KO
mice and histologically analyzed the integrity and distribution of
bile ducts in livers from 4- and 8-week-old male mice. As seen in
Figure 7A, 4-week-old TAK1LPC-KO mice showed scattered CK+
cells with morphological features of biliary epithelium and
hepatic oval cells, whereas the number of these cells strongly
decreased in livers of older mice (R8 weeks of age). In contrast,
TAK1/NEMOLPC-KO mice displayed a strong expansion in CK+
cells from 4 to 8 weeks of age, likely reflecting a sustained regen-
erative response of the intrahepatic biliary system to prevent
ductopenia and cholestasis (Figures 7A and Figure S6A).The Alfp-Cre line used in this study expresses Cre recombi-
nase in LPC (hepatocytes and intrahepatic biliary epithelial cells)
(Kellendonk et al., 2000), suggesting that deletion of Tak1 in both
hepatocytes and biliary epithelial cells might contribute to
ductopenia in these animals. To evaluate a specific function of
TAK1 in cholangiocytes, we performed co-stainings for a biliary
marker (CK) together with markers of apoptosis (cleaved Cas-
pase-3) and proliferation (Ki67) in the different knockout lines.
As seen in Figure 7B, proliferation and, to a lesser extent,
apoptosis were detected in cholangiocytes from TAK1LPC-KO
animals (Figure 7B). On ultrastructural analysis, abnormal biliary
epithelial cells with light cytoplasm and partially disintegrated
nuclei were detected in remnant portal bile ducts of TAK1LPC-KO,
but not WT or TAK1/NEMOLPC-KO livers (Figure 7C), suggesting
that these cells undergo cell death. We further performed
laser-dissection microscopy for A6+-cholangiocytes/oval cells
and compared gene expression patterns between WT and
TAK1LPC-KO A6+ cells and mice with laser-dissected WT hepato-
cytes. Transcriptional analysis for the expression of markers
typical for oval cells and intrahepatic biliary epithelial cells
(Sca-1, Claudin-7, and Epcam) showed strong upregulation
of these markers in oval cells/cholangiocytes from WT and
TAK1LPC-KO mice when compared with laser-dissected WT
hepatocytes, supporting the specificity of the performed laser
dissection procedure (Figure 7D). Further transcriptional anal-
ysis revealed an approximately 3-fold downregulation of Tak1
expression in cholangiocytes/oval cells from TAK1LPC-KO mice
when compared with WT cholangiocytes/oval cells. This
confirms the expected downregulation of TAK1 in all paren-
chymal liver cell compartments (Figure 7D). Similar to the
previous data in whole liver extracts (Figure 6A), mRNA expres-
sion of Afp was on average approximately 7 times higher in
cholangiocytes/oval cells of TAK1LPC-KO when compared with
WT cholangiocytes/oval cells. In contrast, the NF-kB target
gene A20 was downregulated in average 2.4-fold in cholangio-
cytes/oval cells of TAK1LPC-KO livers compared with WT cholan-
giocytes/oval cells. These results suggest that in addition to
hepatocyte-specific effects, cholangiocyte-specific effects of
TAK1-ablation also contribute to ductopenia in TAK1LPC-KO
mice and that ablation of TAK1 in cholangiocytes/oval cells influ-
ences similar signaling pathways and transcriptional targets as
in hepatocytes.
We finally generatedmicewith parenchymal-cell specific dele-
tion of TAK1 using an alternative solely albumin-driven Cre line
(Postic and Magnuson, 2000) (TAK1Dhep) (Figure S6B). TAK1D
hep mice showed many features previously seen in TAK1LPC-KO
mice such as focal necrosis and hepatocyte hyperplasia and
dysplasia (Figures 7E and 7F, Figures S6C and S6D). Moreover,
serological analysis revealed mild hyperbilirubinemia in these
animals that was not as pronounced as seen in TAK1LPC-KO
mice (Figure 7G) and went along with areas of ductopenia within
some portal tracts (Figure 7H). It has been shown that next to
hepatocytes the albumin-cre line can also lead to leaky expres-
sion of Cre-recombinase in intrahepatic cholangiocytes (Xu
et al., 2006), suggesting that not only hepatocyte-specific effects
of TAK1-deletion contribute to the phenotype in TAK1Dhep
mice. However, some periportal areas in TAK1Dhep mice
showed numerous hepatocytes that stained positive for A6,
suggesting their origin from A6-positive oval cells (Figure 7H).Cancer Cell 17, 481–496, May 18, 2010 ª2010 Elsevier Inc. 489
Figure 5. Additional Deletion of NEMO Prevents Cholestasis, but Not Serological Signs of Cell Death, in TAK1LPC-KO Mice
(A) Representative macroscopic pictures of 6-week-old WT, TAK1LPC-KO, NEMOLPC-KO, and TAK1/NEMOLPC-KO livers. No macroscopic alterations or small
nodules could be detected in livers of double-mutant mice.
(B) Cumulative survival of TAK1LPC-KO and TAK1/NEMOLPC-KO mice is shown in a Kaplan-Meier curve. Additional deletion of NEMO prevents spontaneous death
of TAK1LPC-KO mice. ***p < 0.001. TAK1/NEMOLPC-KO (n = 14) and TAK1LPC-KO (n = 9).
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animals was supported by decreased expression of epithelial
markers such as Albumin and C/ebp-b (Figure S6E). These
data suggest that in some areas hepatocyte dysplasia and
hyperplasia might affect biliary integrity in TAK1Dhep and also
TAK1LPC-KO mice.
DISCUSSION
Here, we show that TAK1 controls hepatocyte apoptosis as well
as necrosis and malignant transformation of hepatocytes, and
that TAK1 in hepatocytes and cholangiocytes modulates biliary
integrity and prevents cholestasis. Our data indicate that TAK1
is critical for the activation of NF-kB in response to TNF or LPS
(Figure 8). NEMO- or TAK1-deficient hepatocytes show defec-
tive NF-kB activation in response to LPS leading to hepatocyte
apoptosis and liver failure. Therefore, TAK1 and NEMO are
situated in a linear pathway with nonredundant functions in
NF-kB activation upon TNF or LPS stimulation. The most likely
explanation for this finding is that the kinase function of TAK1
and the recruitment function of NEMO are both needed to phos-
phorylate the catalytic subunits IKK1 and IKK2 in response to
TNF stimulation.
Mice that are not kept under axenic conditions, similar to
humans, are constantly confronted with small doses of LPS orig-
inating from commensal intestinal bacteria and reaching the liver
via the portal vein, where they induce cytokine production by
hepatic immune cells (Enomoto et al., 2002). LPS mediates its
cytotoxic effects on hepatocytes solely via TNF and its receptors
(Leist et al., 1995). Because the mice described here were not
kept under germ-free conditions, it is likely that TNF, which is
strongly upregulated in TAK1LPC-KO mice (see Figure S5A), and
perhaps other TNF family members, are involved in spontaneous
apoptosis and hepatitis in TAK1LPC-KO and NEMOLPC-KOmice. In
line with this hypothesis, it was recently shown that additional
deletion of TNF receptor I (TNFRI) is able to reduce liver damage
and inflammation in mice with TAK1-deficient livers (Inokuchi
et al., 2010).
The linear, nonredundant functions of TAK1 and NEMO in
NF-kB activation explain the similar response to LPS-injection
and represent one important aspect causing hepatitis in both
mouse lines. However, TAK1LPC-KO mice display marked differ-
ences in their phenotype as compared to NEMOLPC-KO mice,
such as excessive dysplasia and cancer development around
5months earlier than NEMOLPC-KO mice. Moreover, lethal chole-
stasis, focal hepatocyte necrosis, as well as ductopenia are
found in TAK1LPC-KO, but not in NEMOLPC-KO mice. Therefore,
TAK1most likely controls additional pathways to hepatocarcino-
genesis. Surprisingly, these additional pathways also depend(C) Analysis of serum ALT, AST, and bilirubin levels in 6-week-old TAK1LPC-KO an
SEM (n = 4 each genotype). ***p < 0.001.
(D) Western blot analysis of whole liver protein extracts from TAK1LPC-KO, TAK1/N
GAPDH served as loading control.
(E) Histological analysis of livers derived from male WT, TAK1LPC-KO, and TAK1
necrosis are seen in TAK1LPC-KO mice (arrowheads), whereas TAK1/NEMOLPC-K
mice did not show areas of nodular hyperplasia with enlarged nuclei as seen in
NEMOLPC-KO mice (arrows).
See also Figure S4.on NEMO, but not on NEMO’s function in NF-kB signaling: the
NF-kB response (e.g., to TNF) is similarly blocked in TAK1LPC-KO
and NEMOLPC-KO, but the additional deletion of Nemo rescues
TAK1LPC-KO mice from dysplasia, necrosis, ductopenia, chole-
stasis and early onset of liver carcinogenesis. These data
demonstrate on a genetic level that TAK1 acts as a gatekeeper
for distinct NEMO functions in hepatocarcinogenesis. In hepato-
cytes with functional TAK1, NEMO acts as a tumor suppressor
by activating NF-kB and preventing spontaneous Caspase-8-
and 3-dependent hepatocyte apoptosis and compensatory
regeneration, reflected by hepatocarcinogenesis in 12-month-
old NEMOLPC-KO mice (Luedde et al., 2007). In contrast, the
absence of TAK1 switches the function of NEMO in hepatocarci-
nogenesis toward a tumor-promoting role, because it mediates
massive hepatocyte dysplasia and early carcinogenesis in an
NF-kB-independent manner (Figure 8).
NEMO as well as TAK1 are recruited to the TNF receptor and
TRAFs via the adaptor protein RIP1 (Adhikari et al., 2007),
whereas receptors that do not rely on RIP1 can recruit TAK1
and NEMO directly via TRAF6 (Karin and Gallagher, 2009).
We provide evidence that absence of TAK1 may promote
increased NEMO-dependent recruitment and activation of other
MAP3 kinases to RIP1 and/or TRAF proteins, which might lead
to a functional gain of these NEMO/RIP1- or NEMO/TRAF
complexes in hepatocarcinogenesis. In line with this hypothesis,
TAK1LPC-KO mice demonstrated a strong increase in MKK4/7
and JNK activation in their livers in response to LPS-injection,
which might contribute to dysplasia and carcinogenesis (Sakurai
et al., 2006). Although increased JNK activation in TAK1-defec-
tive livers correlated with increased phosphorylation of the
MAP3 kinase TAO2, it is likely that also other MAP3 kinases
(like MEKK1, MEKK3, and other candidates) are hyperphos-
phorylated in these cells and might contribute to increased
JNK phosphorylation. Moreover, the functional gain of NEMO
in the absence of TAK1 might also be associated with recruit-
ment of additional RIP1 proteins to the RIP1/NEMO complex
influencing necrotic cell death as recently suggested (Cho
et al., 2009). We finally provided evidence for a possible role of
IKK-dependent phosphorylation of FOXO3a in hepatocarcino-
genesis in TAK1LPC-KO mice. It is presently unclear how
increased FOXO3a phosphorylation is mediated in TAK1-defi-
cient livers, but our data in TAK1/NEMOLPC-KO mice suggest
that this process occurs in an IKK-dependent manner. In
previous studies, direct interactions with other FOXO proteins
have been proposed for TAK1 via Nemo-like kinase (Kim et al.,
2010) as well as for JNK (Essers et al., 2004). The exact molec-
ular interactions between TAK1 and FOXO3a and the functional
role of FOXO3a in the TAK1LPC-KO tumor model need to be clar-
ified in future genetic studies.d TAK1/NEMOLPC-KO mice. Results are shown as mean, and error bars denote
EMOLPC-KO, and littermate control mice (WT), using the indicated antibodies.
/NEMOLPC-KO mice at 6 weeks of age. Upper row: areas of focal hepatocyte
O mice show a complete absence of necrosis. Lower row: TAK1/NEMOLPC-KO
TAK1LPC-KO mice. In portal tracts, biliary structures can be identified in TAK1/
Cancer Cell 17, 481–496, May 18, 2010 ª2010 Elsevier Inc. 491
Figure 6. Mechanisms Driving NEMO-Dependent Dysplasia and Carcinogenesis in TAK1LPC-KO Livers
(A) Quantitative real-time polymerase chain reaction (RT-PCR) analysis on the expression of alpha-fetoprotein (Afp) andH19. All valueswere normalized to b-actin
expression. Results are expressed as mean, and error bars denote SEM. *p < 0.05; **p < 0.01 (n = 5 each genotype).
(B) JNK phosphorylation was assessed by immunoblot analysis of liver protein extracts from TAK1LPC-KO, TAK1/NEMOLPC-KO, and their respective littermate
control mice at the indicated time points after LPS administration using antibodies against phosphorylated JNK, using GAPDH as loading control.
(C) Immunoblot analysis on whole liver protein extracts isolated from the indicated mouse lines after LPS-injection using antibodies detecting the phosphorylated
forms of MKK4, MKK7 and TAO2 using GAPDH as loading control.
(D) Immunoblot analysis of p-FOXO3a, total FOXO3a, p-AKT, and total AKT in liver homogenates of 6-week-old TAK1LPC-KO, TAK1/NEMOLPC-KO, and their
respective littermate control mice (left panel), extracts from dissected liver tumors, and age-matched WT-tissue (middle panel), as well as nonmalignant age-
matched liver tissue (right panel). GAPDH was used as loading control.
See also Figure S5.
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Figure 7. Mechanisms Driving Cholestasis and Ductopenia in TAK1LPC-KO Livers
(A and B) Histological and immunohistochemical analysis on representative liver paraffin sections from 4- to 8-week-old male mice. (A) Upper panels: immuno-
histochemistry for CK demonstrates the presence of small bile ducts in portal areas of 4-week-oldWT, TAK1LPC-KO, and TAK1/NEMOLPC-KO livers. Lower panels:
TAK1LPC-KO mice, but not TAK1/NEMOLPC-KO, mice displayed a clear reduction of small bile ducts at the age of 8 weeks (B) Double stainings of CK with cleaved
Caspase-3 or Ki67 revealed an enhanced proliferation along with apoptosis in the area of portal bile ducts of TAK1LPC-KO and TAK1/NEMOLPC-KO livers (arrows
indicate the area of double-stained cells).
(C) Representative EManalysis of bile duct epithelial cells in livers ofWT, TAK1LPC-KO, and TAK1/NEMOLPC-KOmice. The arrows designate epithelial bile duct cells
undergoing cell death.
(D) Real-time PCR analysis on RNA from laser-dissected A6+ oval cells/cholangiocytes derived from WT and TAK1LPC-KO livers, as well as WT hepatocytes.
Expression of Tak1, Sca-1, Claudin 7, Epcam, Afp, and A20 in cholangiocytes/oval cells and hepatocytes is presented as a heat map.
(E) Representative H/E staining of livers from WT and TAK1Dhep mice. The TAK1Dhep mice showed distinct necrotic areas (arrows).
(F) Quantitative RT-PCR analysis on the expression of H19. All values were normalized to b-actin expression. Results are expressed as mean, and error bars
denote SEM. *p < 0.05; (n = 5 each genotype).
(G) Serum level analysis of total bilirubin in 9-week-old TAK1Dhep and WT mice. Results are shown as mean, and error bars indicate SEM. *p < 0.05 (n = 4 each
genotype).
(H) Histological and immunohistochemical analysis of representative liver sections from 9-week-old TAK1Dhep mice and WT controls. On A6 staining, biliary
ducts were absent in some portal tracts but could be detected in others (lower row). In some areas, hepatocytes stained strongly positive for A6 (upper right
picture).
See also Figure S6.
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revealed an intriguing chromosomal signature, because > 85%
of all investigated HCC displayed amplifications of the whole
chromosome 13 or large portions of it. Moreover, large amplifi-
cations of chromosomes 4 and 8 were also detected in a smaller
proportion of TAK1LPC-KO livers. Interestingly, a specific signa-
ture was not seen in liver tumors from NEMOLPC-KO mice (data
not shown). A further in-detail characterization of the proliferationand differentiation of TAK1LPC-KO HCC clearly indicated a high
proliferation status of TAK1LPC-KO HCC, whereas NEMO LPC-KO
HCC were less proliferative but more differentiated. It has been
previously suggested that IKK subunits might play a role for
the maintenance of genome integrity in an NF-kB-independent
manner (Irelan et al., 2007). Thus, further studies might reveal a
specific molecular connection between the TAK1/NEMO com-
plex and the chromosomal replication machinery, underliningCancer Cell 17, 481–496, May 18, 2010 ª2010 Elsevier Inc. 493
Figure 8. TAK1 Suppresses a Procarcino-
genic Function of NEMO in Hepatocarcino-
genesis
A simplifiedmodel for the roles of TAK1 andNEMO
in hepatocarcinogenesis. Left panel: inWThepato-
cytes, TAK1 and NEMO act in a linear signaling
pathway to activate NF-kB. The catalytic IKK
subunits are recruited to the receptor and RIP1
via NEMO. Activated NF-kB inhibits cleavage of
pro-Caspase-8. In mice with defective NEMO,
IKK1 and IKK2 cannot be recruited to the receptor
and TAK1, leading to blockage of NF-kB activation
and subsequently cleavage of pro-Caspase-8 to
active Caspase-8. Further cleavage of Caspase-3
results in hepatocyte apoptosis associated
with hepatitis and finally hepatocarcinogenesis
in 12-month-old NEMOLPC-KO mice (assigned as
‘‘late carcinogenesis’’). Right panel: in TAK1-
defective hepatocytes, the IKK complex is not acti-
vated in response to stimulation, which is likely
caused by the absence of the TAK1-dependent
kinase activity. Like in NEMO-defective hepato-
cytes (middle panel), the NF-kB pathway cannot
be activated. However, absence of TAK1 results
in a functional gain of NEMO and hyperactivation
of JNK via MKK4 and MKK7. The functional
gain of NEMO is associated with necrosis, dys-
plasia of hepatocytes, biliary ductopenia, and early
HCC development already in 6- to 7-month-old
TAK1LPC-KO livers.
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A Role of TAK1 in Hepatocarcinogenesisthe future potential of the TAK1LPC-KO liver cancermodel for eval-
uating the molecular connection between inflammation and
cancer development.
Our results shed light on the controversial debate on the func-
tion of the NF-kB pathway in hepatocarcinogenesis. It has been
demonstrated that inhibition of NF-kB by conditional expression
of the IkBa superrepressor in hepatocytes inhibited the develop-
ment of liver cancer, suggesting a procarcinogenic function of
NF-kB (Pikarsky et al., 2004). However, later studies targeting
the IKK subunits IKK2 and NEMO had implied a tumor-
suppressor function of this pathway in hepatocarcinogenesis
(Luedde et al., 2007; Maeda et al., 2005). The reason for these
apparently conflicting results has not been clarified to date.
Our results demonstrate that IKK subunits can have distinct
and partly opposing functions from the NF-kB pathway in hepa-
tocarcinogenesis, because NEMO acts as a tumor promoter in
TAK1-deficient hepatocytes independently of NF-kB. Conse-
quently, TAK1 might also receive a gain of function in NEM-
OLPC-KO mice and may potentially mediate procarcinogenic
effects that are absent in the presence of NEMO. Further elucida-
tion of NEMO-dependent functions in hepatocarcinogenesis
promises to reveal specific candidates for prevention and treat-
ment of liver cancer.
EXPERIMENTAL PROCEDURES
Generation of Conditional Knockout Mice for TAK1, NEMO,
TAK1/NEMO, and TAK1/Caspase-8
Mice carrying loxP-site-flanked (floxed) alleles of the TAK1 gene Map3k7
(Tak1Fl) (Sato et al., 2005) and the Nemo gene (NemoFl) (Beraza et al., 2009)
were crossed to Alfp-Cre transgenic mice (Kellendonk et al., 2000) to
generate a liver parenchymal cell-specific knockout of the respective genes494 Cancer Cell 17, 481–496, May 18, 2010 ª2010 Elsevier Inc.(TAK1LPC-KO, NEMOLPC-KO). Mice carrying floxed Caspase-8-allels (Casp8Fl)
were generated (C.L., unpublished data). Mice with double-knockout
of Map3k7/Nemo (TAK1/NEMOLPC-KO) and Map3k7/Caspase-8 (TAK1/
Casp8LPC-KO) in LPC were generated by intercrossing the respective lines.
For generation of TAK1Dhepmice, Tak1Fl mice were crossed to Alb-Cre trans-
genic mice (Postic and Magnuson, 2000). In all experiments, littermates
carrying the respective loxP-flanked alleles but lacking expression of Cre
recombinase were used as WT controls. Mice were bred on a mixed C57/
BL6-SV129Ola genetic background. Only sex-matched animals were com-
pared. All animal experiments were approved by the Federal Ministry for
Nature, Environment and Consumers’ Protection of the state of North Rhine-
Westphalia and were performed in accordance to the respective national,
federal, and institutional regulations.
Liver Injury Models
Liver injury experiments were performed on mice between 6 and 8 weeks of
age. LPS (Sigma) was administered intraperitoneally at a concentration of
25 mg/10 g body weight. Serum ALT, AST, AP, and GLDH activities as well
as total and direct serum bilirubin levels were measured by standard proce-
dures in the Institute of Clinical Chemistry of the RWTH University Hospital
Aachen. Primary hepatocytes were isolated and cultured as previously
described (Luedde et al., 2008) and stimulated with murine recombinant
TNF (10 ng/ml).
Statistics
Results are expressed as themean and standard error of themean or standard
deviation as indicated. Statistical significance between experimental groups
was assessed using an unpaired two-sample t test (Excel). For analysis of
oncogenes and tumor-suppressor genes in HCC from TAK1LPC-KO mice, we
performed: (1) unpaired t test, (2) unpaired t test with log transformation of
the calculated fold change values, and (3) multiple comparison analysis, for
whichp values underwentBonferroni correction. For survival analyses, Kaplan-
Meier survival curves were generated using SPSS software, and statistical
significance was assessed by performing a Cox regression analysis (SPSS).
Statistical calculation of bile ductswas assessed by using aWilcoxon rank test.
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